6-K
GSK plc (GSK)
6-K
2022-09-26
For: 2022-09-26
View Original
Added on
April 10, 2026
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of September 2022
Commission File Number 001-15170
GSK plc
(Translation of registrant's name into English)
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F . . . .X. . . . Form 40-F . . . . . . . .
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ____
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____
SIGNATURES
GSK plc (the 'Company')
Transaction notification
| 1. | Details of PDMR/person closely associated with them<br>('PCA') | |||
|---|---|---|---|---|
| a) | Name | Mr Charles Bancroft | ||
| b) | Position/status | Senior Independent Non-Executive Director | ||
| c) | Initial<br>notification/<br><br><br>amendment | Initial notification | ||
| 2. | Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor | |||
| a) | Name | GSK plc | ||
| b) | LEI | 5493000HZTVUYLO1D793 | ||
| 3. | Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted | |||
| a) | Description<br>of the financial instrument | American Depositary Shares ('ADSs')<br><br><br>ISIN: US37733W2044 | ||
| b) | Nature<br>of the transaction | Acquisition of notional ADSs under the share allocation<br>arrangements for Non-Executive Directors for the period of service<br>from 1 July 2022 to 30 September 2022. | ||
| c) | Price(s)<br>and volume(s) | Price(s) | Volume(s) | |
| $31.02 | 2,673.774 | |||
| d) | Aggregated<br>information | N/A (single transaction) | ||
| Aggregated<br>volume Price | ||||
| e) | Date<br>of the transaction | 2022-09-23 | ||
| f) | Place<br>of the transaction | N/A | ||
| 1. | Details of PDMR/person closely associated with them<br>('PCA') | |||
| --- | --- | --- | --- | --- |
| a) | Name | Dr Anne Beal | ||
| b) | Position/status | Independent Non-Executive Director | ||
| c) | Initial<br>notification/<br><br><br>amendment | Initial notification | ||
| 2. | Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor | |||
| a) | Name | GSK plc | ||
| b) | LEI | 5493000HZTVUYLO1D793 | ||
| 3. | Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted | |||
| a) | Description<br>of the financial instrument | American Depositary Shares ('ADSs')<br><br><br>ISIN: US37733W2044 | ||
| b) | Nature<br>of the transaction | Acquisition of notional ADSs under the share allocation<br>arrangements for Non-Executive Directors for the period of service<br>from 1 July 2022 to 30 September 2022. | ||
| c) | Price(s)<br>and volume(s) | Price(s) | Volume(s) | |
| $31.02 | 448.172 | |||
| d) | Aggregated<br>information | N/A (single transaction) | ||
| Aggregated<br>volume Price | ||||
| e) | Date<br>of the transaction | 2022-09-23 | ||
| f) | Place<br>of the transaction | N/A | ||
| 1. | Details of PDMR/person closely associated with them<br>('PCA') | |||
| --- | --- | --- | --- | --- |
| a) | Name | Dr Hal Dietz | ||
| b) | Position/status | Independent Non-Executive Director | ||
| c) | Initial<br>notification/<br><br><br>amendment | Initial notification | ||
| 2. | Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor | |||
| a) | Name | GSK plc | ||
| b) | LEI | 5493000HZTVUYLO1D793 | ||
| 3. | Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted | |||
| a) | Description<br>of the financial instrument | American Depositary Shares ('ADSs')<br><br><br>ISIN: US37733W2044 | ||
| b) | Nature<br>of the transaction | Acquisition of notional ADSs under the share allocation<br>arrangements for Non-Executive Directors for the period of service<br>from 1 July 2022 to 30 September 2022. | ||
| c) | Price(s)<br>and volume(s) | Price(s) | Volume(s) | |
| $31.02 | 529.657 | |||
| d) | Aggregated<br>information | N/A (single transaction) | ||
| Aggregated<br>volume Price | ||||
| e) | Date<br>of the transaction | 2022-09-23 | ||
| f) | Place<br>of the transaction | N/A | ||
| 1. | Details of PDMR/person closely associated with them<br>('PCA') | |||
| --- | --- | --- | --- | --- |
| a) | Name | Dr Laurie Glimcher | ||
| b) | Position/status | Independent Non-Executive Director | ||
| c) | Initial<br>notification/<br><br><br>amendment | Initial notification | ||
| 2. | Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor | |||
| a) | Name | GSK plc | ||
| b) | LEI | 5493000HZTVUYLO1D793 | ||
| 3. | Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted | |||
| a) | Description<br>of the financial instrument | American Depositary Shares ('ADSs')<br><br><br>ISIN: US37733W2044 | ||
| b) | Nature<br>of the transaction | Acquisition of notional ADSs under the share allocation<br>arrangements for Non-Executive Directors for the period of service<br>from 1 July 2022 to 30 September 2022. | ||
| c) | Price(s)<br>and volume(s) | Price(s) | Volume(s) | |
| $31.02 | 1,684.039 | |||
| d) | Aggregated<br>information | N/A (single transaction) | ||
| Aggregated<br>volume Price | ||||
| e) | Date<br>of the transaction | 2022-09-23 | ||
| f) | Place<br>of the transaction | N/A | ||
| 1. | Details of PDMR/person closely associated with them<br>('PCA') | |||
| --- | --- | --- | --- | --- |
| a) | Name | Dr Jesse Goodman | ||
| b) | Position/status | Independent Non-Executive Director | ||
| c) | Initial<br>notification/<br><br><br>amendment | Initial notification | ||
| 2. | Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor | |||
| a) | Name | GSK plc | ||
| b) | LEI | 5493000HZTVUYLO1D793 | ||
| 3. | Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted | |||
| a) | Description<br>of the financial instrument | American Depositary Shares ('ADSs')<br><br><br>ISIN: US37733W2044 | ||
| b) | Nature<br>of the transaction | Acquisition of notional ADSs under the share allocation<br>arrangements for Non-Executive Directors for the period of service<br>from 1 July 2022 to 30 September 2022. | ||
| c) | Price(s)<br>and volume(s) | Price(s) | Volume(s) | |
| $31.02 | 529.657 | |||
| d) | Aggregated<br>information | N/A (single transaction) | ||
| Aggregated<br>volume Price | ||||
| e) | Date<br>of the transaction | 2022-09-23 | ||
| f) | Place<br>of the transaction | N/A |
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.
| GSK plc | |
|---|---|
| (Registrant) | |
| Date: September<br>26, 2022 | |
| By:/s/ VICTORIA<br>WHYTE<br><br><br>-------------------------- | |
| Victoria Whyte | |
| Authorised<br>Signatory for and on | |
| behalf<br>of GSK plc |